# A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct05521802/  
OnCo record `nct05521802` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell in multiple myeloma, run by Shanghai AbelZeta Ltd., now recruiting.

## Summary

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05521802 by Shanghai AbelZeta Ltd., with 92 participants planned, started 2022-11-11 and due to reach its primary completion in 2024-07. Interventions recorded: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05521802
- Phase: 1/2
- Setting: A Phase Ib/II Study of CBM.BCMA Chimeric Antigen Receptor T Cell Product (C-CAR088) for Treating Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Shanghai AbelZeta Ltd.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT05521802: https://clinicaltrials.gov/study/NCT05521802

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Shanghai AbelZeta](https://onco.cc/companies/shanghai-abelzeta/)

---
JSON: https://onco.cc/api/v1/entities/nct05521802.json